ArticleMicrobial biotechnology2019
Probiotics for preterm infants - time to end all controversies.
Article in Microbial biotechnology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 3 syntheses or guidelines pooled it, 58 citations in OpenAlex.
- Association of Hospital Adoption of Probiotics With Outcomes Among Neonates With Very Low Birth Weight.JAMA health forum · 2023Pooled it
- Probiotic sepsis in preterm neonates-a systematic review.European journal of pediatrics · 2022Pooled it
- Macrolides for the prevention and treatment of feeding intolerance in preterm low birth weight infants: a systematic review and meta-analysis.European journal of pediatrics · 2021Pooled it
- Gut microbiota and metabolome signatures in preterm infants with high versus low risk for neurodevelopmental impairment: a prospective, matched, longitudinal multi-omics study.Frontiers in cellular and infection microbiology · 2026Article
- Review
- Article
- Analysis of Bifidobacterium animalis subsp. lactis BB-12 ® and Lactobacillus rhamnosus GG on underweight and malabsorption in premature infants.Revista da Associacao Medica Brasileira (1992) · 2024Article
- Antibiotic Resistance and Probiotics: Knowledge Gaps, Market Overview and Preliminary Screening.Antibiotics (Basel, Switzerland) · 2023Article
- The Optimal Time for Initiating Probiotics for Preterm and Very-Low-Birth-Weight Infants: A 10-Year Experience in a Single Neonatal Intensive Care Unit.Pediatric gastroenterology, hepatology & nutrition · 2023Article
- A Novel Phytogenic Formulation, EUBIO-BPSG, as a Promising One Health Approach to Replace Antibiotics and Promote Reproduction Performance in Laying Hens.Bioengineering (Basel, Switzerland) · 2023Article
- Leveraging Microbial Symbiosis to Modulate Bronchopulmonary Dysplasia.American journal of respiratory cell and molecular biology · 2023Article
- Predictors of Death in Patients with Neonatal Sepsis in a Peruvian Hospital.Tropical medicine and infectious disease · 2022Article
- Neonatal Morbidities and Feeding Tolerance Outcomes in Very Preterm Infants, before and after Introduction of Probiotic Supplementation.Nutrients · 2022Article
- Increased antibiotic exposure in early life is associated with adverse outcomes in very low birth weight infants.Journal of the Chinese Medical Association : JCMA · 2022Article
- Capturing the antibiotic resistome of preterm infants reveals new benefits of probiotic supplementation.Microbiome · 2022Article
- Understanding the development and function of the gut microbiota in health and inflammation.Frontline gastroenterology · 2022Article
- Enteral Feeding Practices for Very Preterm and Very Low Birth Weight Infants in Nigeria and Kenya.Frontiers in pediatrics · 2022Article
- Current Status of Probiotics for Preterm Infants.Indian journal of pediatrics · 2021Review
- Article
- Probiotics, Prebiotics, and Synbiotics for the Prevention of Necrotizing Enterocolitis.Frontiers in nutrition · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mortality, necrotising enterocolitis (NEC), late onset sepsis (LOS) and feeding intolerance are significant issues for very preterm (< 32 weeks) and extremely preterm (< 28 weeks) infants. The complications of ≥ Stage II NEC [e.g. Resection of the gangrenous gut, survival with intestinal failure, recurrent infections, prolonged hospital stay, and long-term neurodevelopmental impairment (NDI)] impose a significant health burden. LOS also carries significant burden including long-term NDI due to adverse effects of inflammation on the preterm brain during the critical phase of development. Frequent stopping of feeds due to feeding intolerance is a significant iatrogenic contributor to postnatal growth failure in extremely preterm infants. Over 25 systematic reviews and meta-analyses of RCTs (~12 000 participants) have reported that probiotics significantly reduce the risk of all-cause mortality, NEC ≥ Stage II, LOS and feeding intolerance in preterm infants. Systematic reviews and meta-analysis of non-RCTs have also shown that the benefits after adopting probiotics as a standard prophylaxis for preterm infants are similar to those reported in RCTs. No intervention comes close to probiotics when it comes to significant reduction in death, NEC, LOS and feeding intolerance at a cost of less than a dollar a day irrespective of the setting and baseline incidence of NEC. The common controversies that are preventing the rapid uptake of probiotics for preterm infants are addressed in this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.